En Es

Industry News

DIAsource Immunoassays Enters Agreement with ZenTech for RIA Products

By Labmedica International staff writers
31 Jul 2018

Image: DIAsource Immunoassays has entered into an agreement with ZenTech for its portfolio of radioimmunoassays (RIA) products (Photo courtesy of iStock).DIAsource Immunoassays (Brabant Wallon, Belgium), a BioVendor group company, has entered into a strategic agreement with ZenTech (Angleur, Belgium) under which ZenTech will transfer its portfolio of radioimmunoassays (RIA) products to DIAsource, securing their continued production and sales.

DIAsource ImmunoAssays is a diagnostics company specialized in the development, manufacturing, and sales and distribution of immunoassay tests and open instrumentation solutions for clinical diagnostics. It delivers manual RIA and ELISA kits and open automation solutions to the international markets, and has a portfolio of over 190 ELISA and 140 RIA assays. ZenTech specializes in the development, production and commercialization of solutions for clinical diagnostics of early life stage diseases and newborn screening. It has a broad portfolio of products in prenatal, neonatal and pediatric screening and offers complete and flexible solutions to set up the screening activity.

Both the companies have long standing collaborations for more than 15 years, with DIAsource already successfully managing a part of the commercialization of the ZenTech portfolio. The current transfer of RIA products from ZenTech to DIAsource is in line with their strategies. The portfolio to be transferred includes the complete line of special RIAs with thyroid markers and markers for fertility and salt balance. Effective July 24, 2018, DIAsource Immunoassays has assumed commercial ownership of ZenTech’s RIA product portfolio and will service clients from order to shipment, while ZenTech will remain the manufacturer during the transition period in which the production will be transferred to DIAsource. The transfer of production will be done in close collaboration and in phases to be concluded by September 30, 2019.

“Historically, ZenTech had a background and expertise in radioimmunoassays. However, when ZenTech acquired the Belgian company Gamma in 2011, it got access to new technologies and entered the market of newborn screening and early life stage diseases,” said Jean-Claude Havaux, Chairman of the Board, ZenTech. “Today's acquisition of the RIA products by ZenTech’s commercial partner DIAsource will guarantee RIA customers are offered long-term service and excellence in logistics worldwide. This transaction will give ZenTech the opportunity to focus on new innovative product lines and other technologies such as molecular diagnostics and mass spectrometry.”

“This acquisition is yet another step in our strategy to position DIAsource as a consolidator of manual specialty assays, after previous acquisitions of the Intertech RIA product line in 2012 and Viro-Immun ELISA and IFA product lines in 2017. DIAsource also acquired the RIA client businesses from distribution partners in France and Spain in 2015 and 2016. This fourth acquisition in the RIA space demonstrates our commitment to the long term future servicing and support of our large RIA customer base worldwide,” said Jef Vangenechten, CEO of DIAsource Immunoassays. “We experience that RIA remains important as the gold standard for assays that are not available on automated systems or for parameters that require a higher analytical accuracy, whereby manual assays offer benefits in terms of quality and flexibility versus price. DIAsource now has a unique position by combining the most complete offering of RIA specialty assays on the market with the ability to offer various RIA automation solutions. Furthermore our manual assays also allow customization for life science research and screening,” added Vangenechten.

E-mail Print
FaceBook Twitter Google+ Linked in


Develops, manufactures, and markets clinical diagnostic products that focus on endocrinology and infectious diseases
Gold member
More info

More articles about DIASOURCE

19 Sep 2017
DIAsource ImmunoAssays SA Acquires Viro-Immun Diagnostics
DIAsource ImmunoAssays SA, which develops, sells and distributes clinical diagnostics products, has acquired Viro-Immun Diagnostics GmbH, a developer and manufacturer of laboratory diagnostics for the medical diagnosis of infectious and autoimmune diseases.
Read More

Additional news

10 Aug 2018
Global Medical Robots Market to Reach USD 16 Billion by 2023
The global medical robots market is projected to grow at a CAGR of 21.0% from an estimated USD 6.46 billion in 2018 to USD 16.74 billion by 2023, driven by technological advancements, advantages of robot-assisted training in rehabilitation therapy, increased funding for medical robot research, and IPOs issued by medical robot companies. However, safety concerns over robotic surgery devices are expected to limit the market growth to some extent. Recent studies have found a number of technical difficulties and complications experienced while performing procedures using robotic systems. According to the FDA, from 2000 to 2013, surgical robots have been linked to over 144 deaths, over 1,391 injuries, and 8,061 device malfunctions.
Read More
10 Aug 2018
Deep Learning-Based System Detects Lesions in Knee MR Images
Researchers from the department of radiology at the University of Wisconsin School of Medicine and Public Health have developed a deep learning approach to detect cartilage lesions by evaluating MR images of the knee. The researchers used segmentation and classification convolutional neural networks (CNNs) to develop the fully automated deep learning–based cartilage lesion detection system.
Read More
10 Aug 2018
New AI Software Cuts Radiation Therapy Planning Time
Researchers from the University of Toronto have developed automation software that will cut down the time for developing radiation therapy plans — individualized maps that help doctors determine where to blast tumors — from days to mere hours.
Read More
10 Aug 2018
RSNA Announces AI and Machine-Learning Initiatives for 2018
The Radiological Society of North America has planned a diverse roster of machine learning (ML) and artificial intelligence (AI) programming for RSNA 2018 that will focus on the power and potential of AI in radiology and issues associated with implementation.
Read More
10 Aug 2018
Global Market for Machine Learning to Surpass USD 2 Billion by 2023
The global market for machine learning in medical imaging is expected to record a robust growth and surpass USD 2 billion by 2023, driven by benefits such as enhanced productivity, increased diagnostic accuracy, more personalized treatment planning and improved clinical outcomes. However, the market is still in the innovator and early adopter phase, and will need to overcome several barriers before AI becomes mainstream in medical imaging. These are the latest findings of Signify Research, an independent supplier of market intelligence and consultancy to the global healthcare technology industry.
Read More
09 Aug 2018
Stago Connect.One Network Allows Remote Monitoring of Analyzers
Diagnostica Stago, an in-vitro diagnostics company focusing on thrombosis and hemostasis, has launched the secure Connect.One network architecture, which allows laboratories to benefit from remote monitoring of their automated analyzers.
Read More
31 Jul 2018
Report Shows Micro-Machined Ultrasound Transducers Market Growing
Micro-machined ultrasonic transducers (MUTs), in the form of PMUTs (Piezoelectric micro-machined ultrasonic transducers) and CMUTs (capacitive micro-machined ultrasonic transducers), are finally coming to market. New applications, along with improved manufacturing capabilities and advanced technological readiness, are driving the impressive growth of MUTs.
Read More
31 Jul 2018
Machine-Learning Algorithm Analyzes Images to Identify Schizophrenia Patients
A team of researchers from the University of Alberta has developed a machine-learning algorithm to examine functional magnetic resonance imaging (fMRI) images for identifying patients suffering from schizophrenia and ascertaining if they would respond to treatment. In a study, the algorithm examined MRI images of both newly diagnosed, previously untreated schizophrenia patients and healthy subjects and successfully identified patients with schizophrenia at 78% accuracy. It also predicted whether or not a patient would respond positively to a specific antipsychotic treatment named risperidone with 82% accuracy.
Read More
26 Jul 2018
NIH Releases Huge Database of CT Images for AI Testing
The National Institutes of Health’s Clinical Center has made a large-scale dataset of CT images available to the public in order to help the scientific community improve the detection accuracy of lesions. The dataset, named DeepLesion, has over 32,000 annotated lesions identified in CT images, as compared to less than a thousand lesions in most of the publicly available medical image datasets. The images are of 4,400 unique patients, who are partners in research at the NIH and have been completely anonymized. In 2017, the NIH clinical center had released anonymized chest X-ray images and their corresponding data.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions